Answers are grounded in this paper and cite their sources.
To evaluate whether whole-body CT-derived body composition parameters from routine 18 F-FDG PET/CT provide additional prognostic value beyond tumor metabolic activity in patients with stage I-III HER2-negative breast cancer, irrespective of hormone receptor status. In this retrospective study, 178 patients with stage I-III HER2-negative breast cancer who underwent preoperative 18 F-FDG PET/CT were included. Hormone receptor (HR) status was recorded for all patients but was not an eligibility criterion: patients with HER2-negative disease were eligible irrespective of estrogen receptor (ER) and progesterone receptor (PR) status. Whole-body CT images were analyzed using a deep learning-based TotalSegmentator framework to automatically quantify skeletal muscle (SM), visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), and intermuscular adipose tissue (IMAT). Associations between imaging-derived parameters and disease-free survival (DFS) were assessed using Cox proportional hazards models and Kaplan-Meier analysis. The incremental prognostic value of body composition parameters beyond SUVmax was evaluated using Harrell’s C-index, likelihood ratio tests, net reclassification improvement (NRI), and integrated discrimination improvement (IDI). During a median follow-up of 41.0 months, 45 patients (25.3%) experienced DFS events. Compared with the non-DFS event group, patients with DFS events showed significantly higher SUVmax, and increased volumes of IMAT, VAT, and SAT, whereas SM volume and attenuation were significantly lower (all P < 0.05). Multivariable Cox regression analysis demonstrated that higher SUVmax, volumes of IMAT and VAT [HR (95% CI): 4.10 (1.97 ~ 8.55), 3.27 (1.17 ~ 9.15), 3.19 (1.45 ~ 7.00), respectively, p all < 0.05] were associated with increased risk of DFS events, whereas higher SM volume was associated with improved DFS [HR (95% CI): 0.53 (0.29 ~ 0.98), P = 0.045]. The association with IMAT volume was not reproduced when the variable was kept continuous (HR per SD 1.32, 95% CI 0.88 ~ 1.98, P = 0.18). Adding body composition parameters (VAT, IMAT, and SM volumes) to SUVmax improved discrimination, increasing the C-index from 0.71 (95% CI, 0.64 ~ 0.78) to 0.82 (95% CI, 0.77 ~ 0.87; P < 0.001), with improvement in risk reclassification (categorical NRI 0.34, 95% CI 0.07 ~ 0.59, P = 0.008; IDI 0.12, 95% CI 0.04 ~ 0.24, P = 0.004). Among all body composition parameters, VAT volume provided the greatest incremental prognostic value. Furthermore, combined stratification based on SUVmax and VAT volume identified four distinct risk groups, with patients exhibiting both high SUVmax and high VAT volume showing the poorest DFS. In HER2-negative breast cancer patients undergoing preoperative 18 F-FDG PET/CT, higher SUVmax and larger VAT volume were associated with poorer DFS, and larger SM volume with better DFS. Adding body composition parameters to SUVmax improved discrimination modestly, with VAT volume showing the strongest contribution. Patients with both high SUVmax and high VAT volume exhibited the poorest DFS. Further prospective validation in larger, multicentre cohorts is warranted.
No takes yet. Share an insight, caveat, or question.
Yuan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: